TMCnet News
BioAlliance Pharma: Approval of Onxeo's admission to secondary listing and trading on NASDAQ OMX CopenhagenPARIS & COPENHAGEN, Denmark --(Business Wire)-- Regulatory News: In continuation of their joint company announcement of July 23, 2014, BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative company specialized in the development of drugs in orphan oncology diseases newly renamed Onxeo, and Topotarget A/S (NASDAQ OMX Copenhagen - TOPO), today announce that NASDAQ OMX Copenhagen has approved Onxeo's admission to secondary trading and official listing on NASDAQ OMX Copenhagen to be effective as of August 1, 2014. From this date, BioAlliance Pharma as the continuing entity after the merger will also officially operate under the name Onxeo. "We are very happy and proud of this final step marking the starting point for our new identity. Onxeo's teams are ready and determined to unleash their synergistic potential to shape a dynamic player in the orphan oncology market", declares Judith Greciet, Chief Executive Officer of Onxeo. "With the combination of team's expertise and a robust and innovative pipeline, Onxeo has solid basis to successfully conduct its mission to develop innovative drugs and provide patients with hope and significantly improve their lives", declares Anders Vadsholt, Chief Executive Officer of Topotarget. For more information on Onxeo reference is made to the admission prospectus of May 26, 2014 prepared by Onxeo and the company announcements issued by Onxeo, which are available on Onxeo's website (www.bioalliancepharma.com). There has been no adverse material change in Onxeo compared with the information provided in the admission prospectus dated May 26, 2014. BioAlliance Pharma's shares (including the newly issued shares) will remain admitted to trading on Euronext Paris under the name Onxeo (ticker: ONXEO). The exchange of the Topotarget A/S shares against Onxeo's new ordinary shares in accordance with the merger plan is expected to occur on August 5, 2014. Timetable:
About BioAlliance Pharma
About Topotarget
About Onxeo Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (www.bioalliancepharma.com).
|